Eisai Begins Construction Of Antibody Plant In U.S.
This article was originally published in PharmAsia News
Executive Summary
Eisai March 9 announced the start of construction of an antibody drug production site adjacent to its Pennsylvania-based U.S. subsidiary Morphotek